Statement on the Global Fund’s landmark agreement to procure long-acting HIV prevention injectable for low- and middle-income countries

Statement on the Global Fund’s landmark agreement to procure long-acting HIV prevention injectable for low- and middle-income countries

Chris Collins, President and CEO, Friends of the Global Fight:

“This agreement is a transformative moment in the fight against HIV. The global scale-up of lenacapavir could dramatically lower the HIV incidence rate, save lives and enable more countries to eventually take the lead in their own HIV responses. Lenacapavir is potentially game-changing, but only if it is backed up with sufficient resources and the political will to make it widely available. In our new report, Principles of a responsible transition of American leadership to end AIDS: Strategic transition or pandemic resurgence?, we argue that the broad scale up of LEN is central to reducing incidence and advancing transition of the global HIV response to country leadership.”

Global Fund press release